[Cevimeline hydrochloride hydrate (Saligren capsule 30 mg): a review of its pharmacological profiles and clinical potential in xerostomia].
Cevimeline hydrochloride hydrate is a muscarinic receptor agonist with a chemical structure of a quinuclidine. Intraduodenal administration of cevimeline hydrochloride hydrate dose-dependently increased salivary secretion in normal mice and rats, two strains of autoimmune disease mice, and X-irradiated rats. The clinical efficacy of the cevimeline hydrochlide hydrate at 30 mg t.i.d. during 4 weeks has been demonstrated in double blind comparative study with placebo. In addition, its treatments in 52 weeks have increased salivary flow and improved subjective and objective symptoms of patients with xerostomia in Sjögren's syndrome.
Shiozawa
Akira
A
Scientific Affairs Department Pharmaceuticals Group, Nippon Kayaku Co. Ltd., Tokyo Fujimi Bldg., 11-2, Fujimi 1-Chome, Chiyoda-ku, Tokyo 102-8172, Japan. akira.shiozawa@nipponkayaku.co.jp
D000328:Adult; D000818:Animals; D006801:Humans; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology*; D011812:Quinuclidines / Q000494:pharmacology*; D012859:Sjogren's Syndrome / Q000188:drug therapy; D013876:Thiophenes
D018721:Muscarinic Agonists; D011812:Quinuclidines; D013876:Thiophenes; C059240:cevimeline